|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Dicer1/miR-29/HMGCR axis contributes to hepatic free cholesterol accumulation in mouse non- alcoholic steatohepatitis显示文摘Dicer1 是为 microRNA (miRNA ) 的酶必需品成熟。miRNAs 的损失源于 Dicer1 缺乏极大地贡献许多疾病的前进,包括在在非酒精的 steatohepatitis (NASH ) 的发展是批评的免费胆固醇(FC ) 的肝的累积的类脂化合物 dysregulation,而是它的角色遗体逃犯。在这研究,我们使用了肝特定的 Dicer1 大美人老鼠识别涉及肝的 FC 累积的 miRNAs。在一个广泛地使用的饮食的 NASH 模型,老鼠被喂 methionine-choline-deficient (MCD ) 节食 3 个星期,它在肝象 Dicer1 mRNA 层次的减少一样导致了肝的 FC 层次的重要增加。肝特定的 Dicer1 大美人在 5-6 星期导致了肝的 FC 累积,由增加的 mRNA 和 3-hydroxy-3-methylglutaryl 辅酶的蛋白质层次伴随了 reductase (HMGCR ) ,在肝的胆固醇合成的限制率的酶。十一预言 miRNAs 被屏蔽,表明 miR-29a/b/c 显著地压制了由指向 HMGCR mRNA 3-UTR 的 HMGCR 表示。在 SMMC-7721 房间的 miR-29a 的 Overexpression,脂肪变性肝的房间模型,显著地减少的 HMGCR 表示和 FC 铺平。而且, miR-29a 的表达式层次相反地与在 MCD 食谱鼠标的表达式层次在 vitro 在 vivo 并且在肝的房间建模的 2 脂肪变性(SMMC-7721 和 HL-7702 房间) 建模的 HMGCR 被相关。我们的结果证明那 Dicer1/miR-29/HMGCR 轴在老鼠 NASH 贡献肝的免费胆固醇累积,并且 miR-29 可以用作肝的胆固醇动态平衡的一个重要管理者。因此, miR-29a 能为非酒精的脂肪肝疾病的处理以及为与 FC 累积联系的另外的肝疾病作为一个潜在的治疗学的目标被利用。 | Ming-xia LIU Man GAO Chun-zhu LI Cun-zhi YU Hong YAN Chun PENG Yu LI Cheng-gang LI Ze-long MA Yang ZHAO Meng-fan PU Ling-ling MIAO Xin-ming QI Jin RENI | 2017 | Acta Pharmacologica Sinica2017，38，5： | 12 |
| 2 | Molecular breeding of water lily: engineering cold stress tolerance into tropical water lily显示文摘Water lilies(order Nymphaeales)are rich in both economic and cultural values.They grow into aquatic herbs,and are divided into two ecological types:tropical and hardy.Although tropical water lilies have more ornamental and medicinal values compared to the hardy water lily,the study and utilization of tropical water lilies in both landscaping and pharmaceutical use is greatly hindered due to their limited planting area.Tropical water lilies cannot survive the winter in areas beyond 24.3°N latitude.Here,the transgenic pipeline through the pollen-tube pathway was generated for water lily for the first time.To improve cold stress tolerance of tropical water lilies,a gene encoding choline oxidase(CodA)driven by a cold stress-inducible promoter was transformed into a tropical water lily through the pollen-tube transformation.Six independent transgenic lines were tested for survival rate during two winter seasons from 2015 to 2017 in Hangzhou(30.3°N latitude).PCR and southern blot detection revealed that the CodA gene had been integrated into the genome.Reverse transcription PCR showed that CodA gene was induced after cold stress treatment,and further quantitative real-time PCR revealed different expressions among six 4 lines and line 3 had the highest expression.Multiple physiological experiments showed that after cold stress treatment,both the conductivity and malondialdehyde(MDA)levels from transgenic plants were significantly lower than those of non-transgenic plants,whereas the content of betaine and the activity of superoxide dismutase,catalase,and peroxidase were higher than those from non-transgenic plants.These results suggest that expression of exogenous CodA gene significantly improved the cold stress tolerance of tropical water lilies through a wide range of physiological alterations.Our results currently expanded a six-latitude cultivating area of the tropical water lilies.These results not only illuminate the bright future for water lily breeding but will also facilitate the functional genomic studies. | Cuiwei Yu Guirong Qiao Wenmin Qiu Dongbei Yu Shirong Zhou Yan Shen Guanchun Yu Jing Jiang Xiaojiao Han Mingying Liu Liangsheng Zhang Fei Chen Yuchu Chen Renying Zhuo | 2018 | Horticulture Research2018，5，1： | 4 |
| 3 | Adjuvant treatment in biliary tract cancer: To treat or not to treat?显示文摘Biliary tract cancer is a rare malignant tumor. There is limited knowledge about biology and natural history of this disease and considerable uncertainty remains regarding its optimal diagnostic and therapeutic man- agement. The role of adjuvant therapy is object of debate and controversy. Although resection is identified as the most effective and the only potentially curative treatment, there is no consensus on the impact of ad- juvant chemotherapy and/or radiotherapy on the high incidence of disease recurrence and on survival. This is mainly due to the rarity of this disease and the consequent difficulty in performing randomized trials. The only two prospectively controlled trials concluded that adjuvant chemotherapy did not improve survival. Most of the retrospective trials, which had limited sample size and included heterogeneous patients population and non-standardized therapies, suggested a marginal benefit of chemoradiotherapy in reducing locoregional recurrence and an uncertain impact on survival. Welldesigned multi-institutional randomized trials are necessary to clarify the role of adjuvant therapy. Two ongoing phase Ⅲ trials may provide relevant information. | Stefano Cereda Carmen Belli Michele Reni | 2012 | World Journal of Gastroenterology2012，18，21： | 3 |
| 4 | Feasibility and safety of EUS-guided cryothermal ablation in patients with locally advanced pancreatic cancer显示文摘 | Paolo Giorgio Arcidiacono Silvia Carrara Michele Reni Maria Chiara Petrone Stefano Cappio Gianpaolo Balzano Cinzia Boemo Stefano Cereda Roberto Nicoletti Markus Dominik Enderle Alexander Neugebauer Daniel von Renteln Axel Eickhoff Pier Alberto Testoni | 2012 | Gastrointestinal Endoscopy2012，，6： | 3 |
| 5 | Neoadjuvant treatment for resectable pancreatic cancer: Time for phase Ⅲ testing?显示文摘This paper discusses the rationale for phaseⅢtesting of neoadjuvant therapy in patients affected by resectable pancreatic adenocarcinoma.The therapeutic management of patients affected by resectable pancreatic cancer is particularly troublesome due to the aggressiveness of the disease and to the limited efficacy and sometimes unfavourable risk-benefit ratio of the available therapeutic tools.Conflicting data on the role of adjuvant chemoradiation have been reported,while adjuvant single-agent chemotherapy significantly improved overall survival(OS)when compared to surgery alone. However,the OS figures for adjuvant chemotherapy remain disappointing.In effect,pancreatic cancer exhibits a prominent tendency to recur after a brief median time interval from surgery and extra-pancreatic dissemination represents the predominant pattern of disease failure.Neoadjuvant treatment has a strong rationale in this disease but limited information on the efficacy of this approach is available from single arm trials with low levels of evidence.Thus,in spite of two decades of investigation there is currently no evidence to support the routine use of pre-surgical therapy in clinical practice. To foster knowledge on the optimal management of this disease,and to produce evidence-based treatment guidelines,there is no alternative to well designed randomized trials.Systemic chemotherapy is a candidate for testing because it is supported by a more robust rationale than chemoradiation.Combination chemotherapy regimens with elevated activity in advanced disease warrant investigation.Caution would suggest the running of an exploratory phaseⅡrandomized trial before embarking on a large phase Ⅲ study. | Michele Reni | 2010 | World Journal of Gastroenterology2010，16，39： | 2 |
| 6 | Target Therapies in Pancreatic Carcinoma显示文摘 | Nicola Silvestris Antonio Gnoni Anna Elisabetta Brunetti Leonardo Vincenti Daniele Santini Giuseppe Tonini Francesca Merchionne Evaristo Maiello Vito Lorusso Patrizia Nardulli Amalia Azzariti Michele Reni | 2014 | Current Medicinal Chemistry2014，，8： | 2 |
| 7 | Metastatic pancreatic cancer: Is there a light at the end of the tunnel?显示文摘Due to extremely poor prognosis,pancreatic cancer(PDAC)represents the fourth leading cause of cancerrelated death in Western countries.For more than a decade,gemcitabine(Gem)has been the mainstay of first-line PDAC treatment.Many efforts aimed at improving single-agent Gem efficacy by either combining it with a second cytotoxic/molecularly targeted agent or pharmacokinetic modulation provided disappointing results.Recently,the field of systemic therapy of advanced PDAC is finally moving forward.Polychemotherapy has shown promise over single-agent Gem:regimens like PEFG-PEXG-PDXG and GTX provide significant potential advantages in terms of survival and/or disease control,although sometimes at the cost of poor tolerability.The PRODIGE 4/ACCORD 11 was the first phaseⅢtrial to provide unequivocal benefit using the polychemotherapy regimen FOLFIRINOX;however the less favorable safety profile and the characteristics of the enrolled population,restrict the use of FOLFIRINOX to young and fit PDAC patients.The nanoparticle albumin-bound paclitaxel(nab-Paclitaxel)formulation was developed to overcome resistance due to the desmoplastic stroma surrounding pancreatic cancer cells.Regardless of whether or not this is its main mechanisms of action,the combination of nabPaclitaxel plus Gem showed a statistically and clinically significant survival advantage over single agent Gem and significantly improved all the secondary endpoints.Furthermore,recent findings on maintenance therapy are opening up potential new avenues in the treatment of advanced PDAC,particularly in a new era in which highly effective first-line regimens allow patients to experience prolonged disease control.Here,we provide an overview of recent advances in the systemic treatment of advanced PDAC,mostly focusing on recent findings that have set new standards in metastatic disease.Potential avenues for further development in the metastatic setting and current efforts to integratenew effective chemotherapy regimens in earlier stages of disease(neoadjuvant,adjuvant,and multimodal approaches in both resectable and unresectable patients)are also briefly discussed. | Vanja Vaccaro Isabella Sperduti Sabrina Vari Emilio Bria Davide Melisi Carlo Garufi Carmen Nuzzo Aldo Scarpa Giampaolo Tortora Francesco Cognetti Michele Reni Michele Milella | 2015 | World Journal of Gastroenterology2015，21，16： | 2 |
| 8 | 卤素及卤素离子的电子结构[J]显示文摘 | ZeistWJ RenY BickelhauptFM | | 中国化学0，，： | 2 |
| 9 | Inhibition of PDGF, TGF-β, and Abl signaling and reduction of liver fibrosis by the small molecule Bcr-Abl tyrosine kinase antagonist Nilotinib显示文摘 | Yuqing Liu Zhuo Wang Shu Qin Kwong Eric Lik Hang Lui Scott L. Friedman Fu Rong Li Reni Wing Chi Lam Guo Chao Zhang Hui Zhang Tao Ye | 2011 | Journal of Hepatology2011，，3： | 2 |
| 10 | Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase Ⅲ trial显示文摘 | Reni M Cordio S Milandri C | 2005 | Lancet Oncol2005，6，： | 1 |
| 11 | Correlated information and mechanism design显示文摘 | McAfee R Reny P | 1992 | Econometrica1992，60，： | 1 |
| 12 | Estim&tion of urban trMfic conditions using an Autom&tic Vehicle Location (AVL) System显示文摘 | DqAcierno L C&reni A Monteila B | 2009 | European Journ&] of Operation&] Eese&rch2009，196，2： | 1 |
| 13 | Oligodendroglioma 显示文摘 | Van den Bent M J Reni M Gatta G | 2008 | Crit Rev Oncol Hemato12008，66，3： | 1 |
| 14 | Combined treatment with high-dose methotrexate, vincristine and procarbazine, without intrathecal chemotherapy, followed by consolidation radiotherapy for primary central nervous system lymphoma in immunocompetent patients显示文摘 | Ferreri AJ Reni M Dell'OroS | 2001 | Oncology2001，60，2： | 1 |
| 15 | Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience 显示文摘 | Ferreri AJ Blay JY Reni M | 2003 | J Clin Oncol2003，21，2： | 1 |
| 16 | Micro anatomical variations in the cerebellopontine angle associated with retrospective study of 1006 consecutive vestibular schwannomas (acoustics neuronal):abases显示文摘 | Reni D Long DM | 2007 | Neurosurgery2007，92，1： | 1 |
| 17 | Rahitrexed - eloxatin salvage chemotherapy in gemcitabine -resistant metastatic pancreatic cancer显示文摘 | Reni M Pasetto L Aprile G | 2006 | Br J Cancer2006，94，6： | 1 |
| 18 | Size, sprawl, speed and the efficiency of cities 显示文摘 | Reny Prudome Chang- Woo Lee | 1993 | Urban Studies1993，，11： | 1 |
| 19 | Glutamine synthetase activity and HSP70 levels in cultured rat astrocytes: effect of 1-octadecyl-2methylrac-glycero-3phosphocholine显示文摘 | Renis M Cardile V Russo A | 1998 | Brain Res1998，783，： | 1 |
| 20 | Therapeutic management of primary central nervous system lymphoma:lessons from prospective trials显示文摘 | Ferreri AJ Reni M Villa E | 2000 | Ann Oncol2000，11，8： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员